Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
Constellation_Pharmaceuticals
|
| gptkbp:awards |
Various industry awards
|
| gptkbp:CEO |
Jean-Paul_Kress
|
| gptkbp:clinicalTrials |
Phase 3 trials
Immuno-oncology Preclinical development Targeted therapies Monoclonal antibody therapies Early-stage development Late-stage development |
| gptkbp:collaborations |
gptkb:AstraZeneca
gptkb:Bristol-Myers_Squibb gptkb:Janssen_Pharmaceuticals gptkb:Pfizer |
| gptkbp:employees |
~400_(2021)
|
| gptkbp:focus |
Therapeutics
|
| gptkbp:founded |
1992
|
| gptkbp:founder |
Simon_Moroney
|
| gptkbp:headCoach |
~400_(2021)
|
| gptkbp:headquarters |
gptkb:Planegg,_Germany
|
| https://www.w3.org/2000/01/rdf-schema#label |
MorphoSys AG
|
| gptkbp:industry |
Biotechnology
|
| gptkbp:location |
gptkb:Germany
gptkb:North_America Europe |
| gptkbp:market |
€1.5 billion (2021)
|
| gptkbp:notableEvent |
gptkb:Tafasitamab
MOR208 MOR103 MOR202 |
| gptkbp:partnerships |
gptkb:GSK
gptkb:Boehringer_Ingelheim Novartis |
| gptkbp:patentCitation |
Numerous patents in antibody technology
|
| gptkbp:philanthropy |
Supports cancer research initiatives
Supports education in life sciences Supports healthcare access programs |
| gptkbp:products |
Monoclonal antibodies
|
| gptkbp:research |
Biologics
Therapeutics Antibody-drug conjugates |
| gptkbp:researchFocus |
Cancer
Autoimmune diseases |
| gptkbp:revenue |
€100 million (2020)
|
| gptkbp:stockSymbol |
MOR
|
| gptkbp:subsidiary |
MorphoSys_AG_(Switzerland)
MorphoSys_US,_Inc. |
| gptkbp:tradedOn |
gptkb:NASDAQ
gptkb:Frankfurt_Stock_Exchange |
| gptkbp:website |
www.morphosys.com
|